Vodobatinib has been studied in a Phase I trial in patients with CML. Phase II trial is currently enrolling patients failing or intolerant to at least 3 prior tyrosine kinase inhibitors (TKI) including ponatinib globally (NCT02629692 )
Study is recruiting | |
Study design | Open label (no one receives placebo) |
Who can participate in this study | Subjects with Ph+ CML - CP, CML - AP and CML - BP |
Key eligibility criteria |
|
USA | UK | Belgium | France | Italy | Spain | Hungary | Romania | Singapore | Korea